Redeye provides an update following SenzaGen’s Q1 2025 report.
Redeye updates its estimates following Surgical Science’s Q1 2025 report, which beat our projections...
Markets have started turning better Truly decentralised with strong M&A track record Trading at 10x-...
Weak Q1 top line, rapid actions taken We cut '25e-'26e adj.
New CEO is continuing on the strong trajectory We expect 15% yearly organic growth for '25e-'27e Tra...
CEO highlighted importance of product innovation New Bangladesh factory remains core part of strateg...
Earnings growth to pick up from Q2'25e Estimates down given more cautious view on activity pick-up 2...
Director Group Finance emphasised recent milestones.
Zoomability Int AB (”Zoomability” eller ”bolaget”) publicerade den 14 maj 2025 bolagets delårsrappor...
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) har nyligen rapporterat årets f...
Redeye takes a positive stance on Sivers Semiconductors' recent renewal of its debt financing, secur...
Q1 confirms that Terclara defends a leading market position in Sweden and that the Norwegian launch ...
As a consequence of Starbreeze acquiring the publishing rights for Payday 3, the company will now ha...
Q1 was an active quarter for Cantargia. Among other things, positive multiple ascending dose results...
Redeye comments on Enviro’s Q1 report, which presented no real surprises.
Irisity AB (”Irisity” or ”the Company”) published its Q1 report for 2025 on the 13th of May 2025.
Redeye provides its initial take on Navigo’s Q1 2025 report, which slightly missed our estimates.
Redeye provides an initial take following the release of SenzaGen’s Q1 2025 report.
Q1 EBIT SEK 164m (vs. ABSCe 253m) Pome sales biggest contributor, Stor-Skälsjön completed Pome 75% c...
Redeye updates on Better Collective ahead of Q4-results (due 21 May after market close) where focus ...
